|Bid||18.29 x 1000|
|Ask||18.31 x 1100|
|Day's range||17.74 - 18.75|
|52-week range||8.86 - 32.48|
|Beta (5Y monthly)||0.89|
|PE ratio (TTM)||N/A|
|Earnings date||23 Jun 2021 - 28 Jun 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||14 Oct 1999|
|1y target est||18.75|
Rite Aid's (RAD) Q4 results gain from RxEvolution strategy, strength in Elixir brand and robust online growth. However, COVID-related costs woes and lesser cases of cough, cold and flu are concerns.
RAD earnings call for the period ending March 31, 2021.
Rite Aid Corporation (NYSE: RAD) today reported operating results for its fourth quarter and fiscal year ended February 27, 2021.